Gilead Sciences Ranks 68th in Market Activity with $1.078 Billion Trading Volume

On June 3, 2025, Gilead Sciences (GILD) saw a trading volume of $1.078 billion, ranking 68th in the day's market activity. The stock price increased by 0.39%.

Gilead's HIV franchise reported total sales of $19.6 billion in 2024, marking an 8% year-over-year increase. This growth was primarily driven by the strong performance of Biktarvy, the company's leading HIV treatment.

Analyst Michael Yee of Jefferies maintained a Buy rating on Gilead Sciences, setting a price target of $130.00. This rating reflects the company's promising pipeline and strong market position.

Gilead Sciences has received a consensus Buy recommendation from analysts, with price targets ranging from $92 to $140. This positive outlook is supported by the company's extensive portfolio, which includes critical therapeutic areas such as HIV/AIDS, COVID-19, viral hepatitis, oncology, and pulmonary arterial hypertension.

Gilead Sciences is awaiting an FDA decision on Lenacapavir, an investigational twice-yearly treatment for HIV prevention. The first clinical data for Lenacapavir was presented at CROI 2025 and published in The Lancet, highlighting its potential as a groundbreaking therapy in HIV prevention.